ProCE Banner Activity

COSMIC-021 Cohort 2 Expansion: Phase Ib Study of Cabozantinib Plus Atezolizumab in Urothelial Carcinoma After Prior Platinum Chemotherapy

Slideset Download
Conference Coverage
Cabozantinib plus atezolizumab resulted in durable tumor responses with tolerable toxicity in patients with urothelial carcinoma previously treated with platinum-based chemotherapy.

Released: June 01, 2020

Expiration: May 31, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono